Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278504 | 0.85 | TDP1 (0.62) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL6576203 | 0.83 | TDP1 (0.60) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL4922982 | 0.83 | TDP1 (0.60) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL6646572 | 0.83 | TDP1 (0.60) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL5042301 | 0.80 | TDP1 (0.56) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL31514206 | 0.80 | TDP1 (0.56) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL5035521 | 0.79 | TDP1 (0.55) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL278488 | 0.77 | TDP1 (1.00) | TDP1TSHRMAPK1ALDH1A1VCAM1 | |
| SCHEMBL29975243 | 0.77 | ALDH1A1 (0.53) | TDP1TSHRMAPK1ALDH1A1 | |
| SCHEMBL10756135 | 0.77 | ALDH1A1 (0.53) | TDP1TSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059685-A1 | PIEZO1 AGONISTS FOR THE PROMOTION OF BONE FORMATION | BIOVENTURES, LLC | 2024-02-22 | — | — | US | disclosed |
| WO-2021067943-A1 | PIEZO1 AGONISTS FOR THE PROMOTION OF BONE FORMATION | BIOVENTURES, LLC (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067943-A1 | PIEZO1 AGONISTS FOR THE PROMOTION OF BONE FORMATION | BIOVENTURES, LLC (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-0807105-B1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0605499-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO 4,5,1-jk] 1,4]-BENZODIAZEPIN-2(1H -)-THIONES | JANSSEN PHARMACEUTICA NV (BE) | 1997-11-12 | — | — | EP | disclosed |
| US-5599982-A | Process for preparing enantiomerically pure imidazo[4,5,1-JK][1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-02-04 | — | — | US | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
| US-5463049-A | Process for preparing enantiomerically pure imidazo[4,5,1-JK][1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-10-31 | — | — | US | disclosed |
| EP-0534539-A1 | Process for preparing enantiomerically pure imidazo[4,5,1-jk]-[1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059685-A1 | PIEZO1 AGONISTS FOR THE PROMOTION OF BONE FORMATION | PIEZO1, TMEM63A, SOST | TDP1 3468/4885TSHR 613/4885MAPK1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.